Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zhuyong Mei
Observed names:
Mei Zhuyong,
Mei, Zhuyong,
Z. Mei
Institution:
Baylor College of Medicine
Observed institutions:
Houston Methodist,
St. Jude Children's Research Hospital,
Royal Adelaide Hospital,
University of Tennessee Health Science Center,
Baylor College of Medicine,
Texas Children's Hospital,
Le Bonheur Children's Hospital,
Dan L Duncan Comprehensive Cancer Center
show all 8
ORCID:
0000-0002-8843-5767
Observed ORCID:
0000-0002-8843-5767
OpenAlex ID:
A5073093199
Works
66
Awards
1
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
2008
·
Martin A Pule
, Barbara Savoldo
, et al.
·
Nature Medicine
·
1,258
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
2011
·
Chrystal U. Louis
, Barbara Savoldo
, et al.
·
Blood
·
1,249
PDF
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
2011
·
Barbara Savoldo
, Carlos Almeida Ramos
, et al.
·
Journal of Clinical Investigation
·
1,086
Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
2015
·
Nabil Ahmed
, Vita S. Brawley
, et al.
·
Journal of Clinical Oncology
·
1,075
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
2017
·
Andras Heczey
, Chrystal U. Louis
, et al.
·
Molecular Therapy
·
557
PDF
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
2013
·
Conrad Russell Y. Cruz
, Kenneth P. Micklethwaite
, et al.
·
Blood
·
526
Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
2017
·
Carlos A. Ramos
, Brandon Ballard
, et al.
·
Journal of Clinical Investigation
·
394
PDF
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
2024
·
David Steffin
, Nisha Ghatwai
, et al.
·
Nature
·
339
PDF
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas
2018
·
Carlos A. Ramos
, Rayne Rouce
, et al.
·
Molecular Therapy
·
331
PDF
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
2016
·
Carlos A. Ramos
, Barbara Savoldo
, et al.
·
Journal of Clinical Investigation
·
296
PDF
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
2012
·
Natalia Lapteva
, April G. Durett
, et al.
·
Cytotherapy
·
234
Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia
2017
·
Michael Boyiadzis
, Mounzer Agha
, et al.
·
Cytotherapy
·
192
Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System
2014
·
Patrick J. Hanley
, Zhuyong Mei
, et al.
·
Cytotherapy
·
174
Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma
2003
·
Raphaël F. Rousseau
, Ann E. Haight
, et al.
·
Blood
·
129
PDF
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors
2024
·
Frank Y. Lin
, Austin Stuckert
, et al.
·
Journal of Clinical Oncology
·
97
PDF
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation
2005
·
Raphaël F. Rousseau
, Ettore Biagi
, et al.
·
Blood
·
76
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
2023
·
LaQuisa C. Hill
, Rayne H. Rouce
, et al.
·
Blood
·
74
Manufacturing mesenchymal stromal cells for phase I clinical trials
2013
·
Patrick J. Hanley
, Zhuyong Mei
, et al.
·
Cytotherapy
·
64
Autologous Antileukemic Immune Response Induced by Chronic Lymphocytic Leukemia B Cells Expressing the CD40 Ligand and Interleukin 2 Transgenes
2001
·
Satoshi Takahashi
, Raphael F. Rousseau
, et al.
·
Human Gene Therapy
·
63
Bacterial LPS and IFN-γ trigger the tyrosine phosphorylation of vav in macrophages: evidence for involvement of the hck tyrosine kinase
1997
·
B Keith English
, Shari L Orlicek
, et al.
·
Journal of Leukocyte Biology
·
53
Phase I Trial of Vaccination With Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 and Lymphotactin
2007
·
Heidi V. Russell
, Douglas Strother
, et al.
·
Journal of Immunotherapy
·
51
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
2022
·
Kai Sun
, Yitian Xu
, et al.
·
Clinical Cancer Research
·
42
A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma
2008
·
Heidi V. Russell
, Douglas Strother
, et al.
·
Journal of Immunotherapy
·
38
Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma
2001
·
Satoshi Takahashi
, Patricia Yotnda
, et al.
·
Cancer Gene Therapy
·
36
T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC
2017
·
Arpad Szoor
, Abishek Vaidya
, et al.
·
Molecular Therapy — Oncolytics
·
34
PDF
Show more works
View as search
Works count:
66
Citation count:
8,665
H-index:
26
I10-index:
32
Year
Topic
Type